Recent Updates
Recently added Catalysts
TAK Positive Sentiment

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Monday, October 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Takeda announced new findings from the VERDICT trial, demonstrating that treating ulcerative colitis with ENTYVIO® to achieve corticosteroid-free disease clearance significantly prolongs the time to the first complication related to the disease. The results indicate a nearly 70% reduction in the risk of complications compared to symptomatic remission alone.

Market Sentiment Analysis

POSITIVE FACTORS

  • Significantly prolongs time to first UC-related complication.
  • Reduces UC complication risk by nearly 70%.
  • First trial to show benefits of treating to disease clearance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
NDI-034858 study drug
NDA/BLA · Moderate to Severe Plaque Psoriasis

Full Press Release Details

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent

Frequently Asked Questions

What is the main finding of the VERDICT trial?

The trial found that treating with ENTYVIO® for disease clearance prolongs time to UC complications.

How much does ENTYVIO® reduce UC complication risk?

ENTYVIO® reduces the risk of UC complications by nearly 70%.

What does CSF stand for in the trial results?

CSF stands for corticosteroid-free.

What is the significance of this trial?

It's the first trial to show benefits of treating to disease clearance in UC.

ShareAdd on Google
Tags: TAK Takeda ENTYVIO ulcerative colitis clinical trial VERDICT
Last updated: Oct 19, 2026

Biotech snapshot

Lead asset
NDI-034858 study drugNDA/BLA
Moderate to Severe Plaque Psoriasis →

Catalyst track record

+27%
best trade around TAK's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for TAK.

See every catalyst's timing & PoA →